CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 124 enrolled
Drug / intervention
Ibrutinib +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02403271
NCT02403271Phase 2Completed
CompareCT.gov

A Multi-Center Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination With Durvalumab (MEDI4736), in Subjects With Relapsed or Refractory Solid Tumors

Pharmacyclics LLC.·interventional·Posted Mar 31, 2015·Updated Jan 3, 2019

In Brief

A Phase 2 clinical trial evaluating Ibrutinib and Durvalumab for Non-Small Cell Lung Cancer and 2 related conditions. Completed, enrolled 124 participants across 17 sites.

Detailed Summary

This is a Phase 1b/2, multi-center study to assess the safety and efficacy of ibrutinib in combination with durvalumab (MEDI4736) in participants with relapsed or refractory solid tumors.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNon-Small Cell Lung Cancer, Breast Cancer, Pancreatic Cancer
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
First PostedMar 31, 2015
Enrollment StartMar 1, 2015
Primary CompletionAug 1, 2017
TodayJul 2, 2026
Enrollment to primary: 2.4 yearsPosted 11.3 years ago

Interventions

Ibrutinibdrug

BTK Inhibitor

Durvalumabdrug

Anti PDL-1